Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10015756HBVENSG00000051382.10protein_codingPIK3CBYesNo5291P42338
TVIS10004985HBVENSG00000051382.10protein_codingPIK3CBYesNo5291P42338
TVIS10004986HBVENSG00000051382.10protein_codingPIK3CBYesNo5291P42338
TVIS10029385HBVENSG00000051382.10protein_codingPIK3CBYesNo5291P42338
TVIS10045106HBVENSG00000051382.10protein_codingPIK3CBYesNo5291P42338
TVIS10045750HBVENSG00000051382.10protein_codingPIK3CBYesNo5291P42338
TVIS30003580HIVENSG00000051382.10protein_codingPIK3CBYesNo5291P42338
TVIS30082600HIVENSG00000051382.10protein_codingPIK3CBYesNo5291P42338
TVIS30058491HIVENSG00000051382.10protein_codingPIK3CBYesNo5291P42338
TVIS30058492HIVENSG00000051382.10protein_codingPIK3CBYesNo5291P42338
TCGA Plot Options
Drug Information
GenePIK3CB
DrugBank IDDB12483
Drug NameCopanlisib
Target IDBE0002407
UniProt IDP42338
Regulation Typeinhibitor
PubMed IDs29127587; 30147333
CitationsMarkham A: Copanlisib: First Global Approval. Drugs. 2017 Dec;77(18):2057-2062. doi: 10.1007/s40265-017-0838-6.@@Mensah FA, Blaize JP, Bryan LJ: Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. Onco Targets Ther. 2018 Aug 13;11:4817-4827. doi: 10.2147/OTT.S142264. eCollection 2018.
GroupsApproved; Investigational
Direct ClassificationQuinazolinamines
SMILESCOC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21
Pathways
PharmGKB
ChEMBLCHEMBL3218576